Clinical Insights

More

Expanded Applications of AI in Lysosomal Disorders

Expanded Applications of AI in Lysosomal Disorders

How AI is advancing disease modeling and biomarker development and advancing therapeutic target identification across lysosomal disorders

Recent Videos

Social Wall

CheckRare is excited to once again serve as a media partner for the World Orphan Drug Congress.

This event brings together leaders, innovators, advocates, and experts from across the rare disease community to share insights, discuss emerging trends, and explore opportunities to

James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with seronegative generalized myasthenia gravis (gMG). Data from this trial was pivotal in

Even though the ligneous lesions on the eye are generally the first symptom of PLGD-1, the deficiency can present in many different ways (and in virtually any organ system with mucous membranes).

Learn about the key features of disease at ...https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency-2/

#CheckRare

Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis

📢 May 2026 FDA Milestones in Rare Disease Care!

Stay up to date with our 2026 PDUFA Dates and FDA Approvals page at https://checkrare.com/2026-orphan-drugs-pdufa-dates-and-fda-approvals/

#RareDisease #FDAApproval #MedicalBreakthroughs #CheckRare